natgillin/translations-raw huggingface dataset:
This is not likely to be relevant for humans given recommended nasal doses which results in minimal systemic exposure (see section 5.2). 
Malo je verjetno, da bi bili ti izsledki pomembni za uporabo priporočenih nazalnih odmerkov pri človeku, pri katerih je dosežena minimalna sistemska izpostavljenost (glejte poglavje 5.2).
• Once symptoms are controlled you may be able to decrease your dose to 1 spray in each nostril, 
• Ko bodo simptomi pod nadzorom, boste odmerek morda lahko zmanjšali na 1 vpih v vsako nosnico enkrat na dan.
Increases in IOP (7 mmHg from baseline) were more frequent in subjects treated with fluticasone furoate 110 micrograms: 7 (2%) for fluticasone furoate 110 micrograms once daily and 1 (<1%) for placebo. 
Zvišanje očesnega tlaka ( 7 mmHg od izhodišča) je bilo pogostejše pri preiskovancih, zdravljenih s 110 mikrogrami flutikazonfuroata: 7 (2 %) s 110 mikrogrami flutikazonfuroata enkrat na dan in 1 (< 1 %) s placebom.
Also contains: Glucose anhydrous, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, purified water. 
Vsebuje tudi: brezvodno glukozo, disperzibilno celulozo, polisorbat 80, benzalkonijev klorid, dinatrijev edetat in prečiščeno vodo.
• ritonavir or cobicistat, used to treat HIV 
• ritonavir ali kobicistat, ki ju uporabljamo pri zdravljenju okužbe z virusom HIV,
Increases in posterior subcapsular opacity or IOP were not accompanied by any adverse events of cataracts or glaucoma. 
Povečanja posteriorne subkapsularne motnosti ali zvišanja očesnega tlaka nista spremljala neželena učinka katarakta ali glavkom.
The increase in fluticasone furoate systemic exposure in subjects with moderate hepatic impairment (fluticasone furoate/vilanterol 200/25 micrograms) was associated with an average 34% reduction in serum cortisol compared with healthy subjects. 
Povečanje sistemske izpostavljenosti flutikazonfuroatu je bilo pri preiskovancih z zmerno okvaro jeter (flutikazonfuroat/vilanterol 200/25 mikrogramov) povezano s povprečno 34 % znižanjem kortizola v serumu v primerjavi z zdravimi preiskovanci.
• The usual starting dose is 1 spray in each nostril once a day. 
• Priporočeni začetni odmerek je 1 vpih v vsako nosnico enkrat na dan.
Increases in posterior subscapsular opacity (0.3 from baseline) were more frequent in subjects treated with fluticasone furoate 110 micrograms [14 (4%)] versus placebo [4 (2%)] and were transient in nature for ten subjects in the fluticasone furoate group and two subjects in the placebo group. 
Povečanje posteriorne subkapsularne motnosti ( 0,3 od izhodišča) je bilo pogostejše pri preiskovancih, zdravljenih s 110 mikrogrami flutikazonfuroata [14 (4 %)], kot pri prejemnikih placeba [4 (2 %)], ter je bilo prehodno pri desetih preiskovancih v skupini s flutikazonfuroatom in pri dveh preiskovancih v skupini s placebom.
Concomitant administration with ritonavir is not recommended because of the risk of increased systemic exposure of fluticasone furoate (see section 4.5). 
Zaradi tveganja za večjo sistemsko izpostavljenost flutikazonfuroatu sočasne uporabe ritonavirja ne priporočamo (glejte poglavje 4.5).
• Avamys comes in an amber glass bottle. 
• Zdravilo Avamys je na voljo v steklenički jantarne barve.
Administration of fluticasone furoate to women who are breast-feeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child. 
Flutikazonfuroat se sme med dojenjem uporabljati le, če koristi za mater prevladajo nad kakršnimkoli tveganjem za dojenega otroka.
study of a single 400 microgram dose of orally inhaled fluticasone furoate in patients with moderate hepatic impairment (Child-Pugh B) resulted in increased Cmax (42 %) and AUC(0-∞) (172 %) and a modest (on average 23 %) decrease in cortisol levels in patients compared to healthy subjects. 
V študiji z enim samim 400 mikrogramskim odmerkom peroralno inhaliranega flutikazonfuroata pri bolnikih z zmerno okvaro jeter (Child-Pugh B) sta se, v primerjavi z zdravimi osebami, pri bolnikih povečali vrednosti Cmax (42 %) in AUC(0-) (172 %), vrednosti kortizola pa zmerno zmanjšale (v povprečju za 23 %).
The values are similar to those seen in adults (12+) where median concentrations in those subjects with quantifiable levels were 15.4 pg/ml and 21.8 pg/ml at 55 micrograms and 110 micrograms, respectively. 
Vrednosti so podobne vrednostim pri odraslih (12+), pri katerih je bila po uporabi 55 mikrogramskega odmerka mediana vrednost koncentracij 15,4 pg/ml, po uporabi 110 mikrogramskega odmerka pa 21,8 pg/ml.
A reduction in growth velocity has been observed in children treated with fluticasone furoate 110 micrograms daily for one year (see section 4.8 and section 5.1). 
Pri otrocih, ki so eno leto prejemali 110 mikrogramov flutikazonfuroata na dan, so opažali upočasnitev rasti (glejte poglavji 4.8 in 5.1).
The other ingredients are glucose anhydrous, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, purified water (see section 2). 
Pomožne snovi so brezvodna glukoza, disperzibilna celuloza, polisorbat 80, benzalkonijev klorid, dinatrijev edetat in prečiščena voda (glejte poglavje 2).
The intranasal dosing of 110 micrograms once daily does not typically result in measurable plasma concentrations (<10 pg/ml). 
Pri nazalni uporabi odmerka 110 mikrogramov enkrat na dan plazemske koncentracije tipično niso merljive (< 10 pg/ml).
However the dose of intranasal fluticasone furoate should be reduced to the lowest dose at which effective control of the symptoms of rhinitis is maintained. 
Odmerek nazalnega flutikazonfuroata pa je kljub temu treba zmanjšati na najmanjši odmerek, ki še zagotavlja učinkovito nadzorovanost simptomov rinitisa.
Fluticasone furoate is widely distributed with volume of distribution at steady-state of, on average, 608 l. 
Volumen porazdelitve v stanju dinamičnega ravnovesja je v povprečju 608 litrov.
Urinary excretion accounted for approximately 1 % and 2 % of the orally and intravenously administered dose, respectively. 
Pri peroralni uporabi se je z urinom izločilo približno 1 % prejetega odmerka, pri intravenski uporabi pa približno 2 % prejetega odmerka.
The bottle is in an off-white plastic casing with a light blue cap and side-actuated lever. 
Steklenička je vložena v sivo plastično ohišje s svetlomodrim pokrovčkom in sprožilcem ob strani.
The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. 
Odmerek je treba titrirati do najmanjšega odmerka, s katerim se lahko učinkovito obvladuje simptome.
4 Press the button firmly all the way in. Do this at least 6 times until it releases a fine mist of spray into the air - see picture f. 
Naredite to vsaj 6-krat, dokler pršilo v zrak ne sprosti drobne meglice - glejte sliko f.
The most commonly reported adverse reactions during treatment with fluticasone furoate are epistaxis, nasal ulceration and headache. 
Najpogosteje opisani neželeni učinki med zdravljenjem s flutikazonfuroatom so krvavitev iz nosu, razjede nosne sluznice in glavobol.
Children 6 to 11 years 
Uporaba pri otrocih, starih od 6 do 11 let
Avamys has no or negligible influence on the ability to drive and use machines. 
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Zdravilo Avamys nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
3 Never use a pin or anything sharp on the nozzle. 
3 Na nastavku nikoli ne uporabite igle ali česa drugega ostrega.
In seasonal allergic rhinitis, fluticasone furoate nasal spray 110 micrograms once daily was effective but no significant differences were observed between fluticasone furoate nasal spray 55 micrograms once daily and placebo on any endpoint. 
Pri sezonskem alergijskem rinitisu se je flutikazonfuroat v obliki pršila za nos v odmerku 110 mikrogramov enkrat na dan izkazal za učinkovitega, vendar pa pri nobenem opazovanem dogodku niso opazili pomembne razlike med flutikazonfuroatom v obliki pršila za nos v odmerku 55 mikrogramov enkrat na dan in placebom.
At weeks 52 and 104, 95% of subjects in both treatment groups had posterior subcapsular opacity values within ± 0.1 of baseline values for each eye and, at week 104, ≤1% of subjects in both treatment groups had 0.3 increase from baseline in posterior subcapsular opacity. 
Po 52 in 104 tednih je imelo 95 % preiskovancev v obeh terapevtskih skupinah na enem in drugem očesu posteriorno subkapsularno motnost znotraj ± 0,1 od izhodiščne vrednosti.
The medicine is a white nasal spray suspension contained in an amber glass bottle, fitted with a pump. 
Pršilo za nos je bela suspenzija v steklenički jantarne barve, zaprti s pršilnikom.
EXPIn-use shelf life: 2 months 
EXP Rok uporabnosti po prvem odprtju: 2 meseca
Following repeat dosing of orally inhaled fluticasone furoate/vilanterol for 7 days, there was an increase in fluticasone furoate systemic exposure (on average two-fold as measured by AUC(0-24)) in subjects with moderate or severe hepatic impairment (Child-Pugh B or C) compared with healthy subjects. 
Po ponavljajočem se odmerjanju peroralno inhalirane kombinacije flutikazonfuroat/vilanterol v obdobju 7 dni se je sistemska izpostavljenost flutikazonfuroata pri preiskovancih z zmerno ali hudo okvaro jeter (Child-Pugh B ali C) v primerjavi z zdravimi preiskovanci povečala ( v povprečju za dvakrat, merjeno z AUC(0-24)).
Preparing the nasal spray for use 
Priprava pršila za nos za uporabo
Treatment with higher than recommended doses of nasal corticosteroids may result in clinically significant adrenal suppression. 
Pri zdravljenju z nazalnimi kortikosteroidi v odmerkih, večjih od priporočenih, se lahko pojavi klinično pomembna zavora delovanja nadledvičnih žlez.
Very common side effects (may affect more than 1 in 10 people) • Nosebleeds (generally minor), particularly if you use Avamys for more than 6 weeks continuously. 
• krvavitve iz nosu (običajno blažje), še posebej, če zdravilo Avamys uporabljate neprekinjeno dlje kot 6 tednov.
Patients not adequately responding to one spray actuation in each nostril once daily (total daily dose, 55 micrograms) may use two spray actuations in each nostril once daily (total daily dose, 110 micrograms). 
Bolniki, ki se na zdravljenje z enim vpihom v vsako nosnico enkrat na dan (skupni dnevni odmerek 55 mikrogramov) ne odzovejo dovolj, lahko uporabljajo dva vpiha v vsako nosnico enkrat na dan (skupni dnevni odmerek 110 mikrogramov).
Follow these steps: 1 Shake the nasal spray vigorously with the cap on for about 10 seconds. 
Sledite naslednjim korakom: Pršilo za nos z nameščenim pokrovčkom približno 10 sekund močno stresajte.
Compared with placebo, fluticasone furoate nasal spray 110 micrograms once daily significantly improved nasal symptoms (comprising rhinorrhoea, nasal congestion, sneezing and nasal itching) and ocular symptoms (comprising itching/burning, tearing/watering and redness of the eyes) in all 4 studies. 
Sezonski alergijski rinitis pri odraslih in mladostnikih V primerjavi s placebom je flutikazonfuroat v obliki pršila za nos v odmerku 110 mikrogramov enkrat na dan v vseh 4 študijah pomembno izboljšal nosne simptome (ki so obsegali nosni izcedek, kongestijo nosne sluznice, kihanje in srbenje nosu) in očesne simptome (ki so obsegali srbenje/pekoč občutek v očeh, solzenje/izcedek iz oči in rdečino oči).
GlaxoSmithKline (Malta) Limited Tel: + 356 21 238131 
GlaxoSmithKline (Malta) Linited Tel: + 356 21 238131
Quantifiable levels were observed in 15.1 % of paediatric patients following intranasal dosing of 110 micrograms once daily and only 6.8 % of paediatric patients following 55 micrograms once daily. 
Po nazalnem odmerku 110 mikrogramov enkrat na dan so bile merljive vrednosti opažene pri 15,1 % otrok, po odmerku 55 mikrogramov enkrat na dan pa le pri 6,8 % otrok.
Fluticasone furoate is not detectable in urine from healthy volunteers after intranasal dosing. 
Po nazalni uporabi pri zdravih prostovoljcih flutikazonfuroata v urinu ni bilo mogoče dokazati.
Systemic effects of nasal corticosteroid may occur, particularly at high doses prescribed for prolonged periods. 
Pojavijo se lahko sistemski učinki nazalnih kortikosteroidov, še posebej pri uporabi visokih odmerkov daljši čas.
Once adequate control of symptoms is achieved, dose reduction to one spray actuation in each nostril once daily (total daily dose, 55 micrograms) is recommended. 
Ko je dosežen zadosten nadzor simptomov, priporočamo zmanjšanje odmerka na en vpih v vsako nosnico enkrat na dan (skupni dnevni odmerek 55 mikrogramov).
Safety and efficacy studies were performed in a total of 271 patients from 2 to 5 years of age in both seasonal and perennial allergic rhinitis, of whom 176 were exposed to fluticasone furoate. 
Študije varnosti in učinkovitosti so bile izvedene pri skupaj 271 bolnikih, starih od 2 do 5 let, tako pri sezonskem kot celoletnem alergijskem rinitisu.
4 Always replace the cap once you have finished. 
4 Po koncu vedno namestite pokrovček nazaj.
Fluticasone furoate is rapidly cleared by extensive first pass metabolism mediated by the cytochrome P450 3A4. 
Medsebojno delovanje z zaviralci CYP3A4 Flutikazonfuroat se hitro očisti z obsežno presnovo prvega prehoda s citokromom P450 3A4.
The device should be cleaned after each use and the cap replaced. 
Po vsaki uporabi je treba pršilnik očistiti in ga pokriti s pokrovčkom.
3 Hold the nasal spray upright, then tilt and point the nozzle away from you. 
Držite pršilo za nos pokonci, potem ga nagnite in usmerite nastavek proč od sebe.
GlaxoSmithKline Latvia SIA Tel: + 371 67312687 lv-epasts@gsk.com 
GlaxoSmithKline Latvia SIA Tel: + 371 67312687 lv-epasts@gsk.com Lietuva
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Preobčutljivost za zdravilno učinkovino ali katerokoli pomožno snov, navedeno v poglavju 6.1. 4.4 Posebna opozorila in previdnostni ukrepi
Seasonal and perennial allergic rhinitis in children: 
Sezonski in celoletni alergijski rinitis pri otrocih:
Driving and using machines Avamys is unlikely to affect your ability to drive and use machines. 
Vpliv na sposobnost upravljanja vozil in strojev Verjetnost vpliva zdravila Avamys na sposobnost upravljanja vozil in strojev je majhna.
Children and adolescents Do not use in children under 6 years old. 
Tega zdravila ne uporabljajte pri otrocih, mlajših od 6 let.
• Never use a pin or anything sharp to clear the nozzle. 
• Za čiščenje nastavka nikoli ne uporabite igle ali česa drugega ostrega.
It is recommended that the growth of children receiving prolonged treatment with nasal corticosteroids is regularly monitored. 
Otrokom, ki dolgo časa prejemajo nazalne kortikosteroide, je priporočljivo redno kontrolirati rast.
• steroid creams 
• kortikosteroidne kreme,
No genotoxic effects of fluticasone furoate have been observed in conventional genotoxicity tests. 
Pri običajnih preskušanjih genotoksičnosti genotoksičnega delovanja flutikazonfuroata niso ugotovili.
Elderly Patients No dose adjustment is required in this population (see section 5.2). 
Starejši bolniki Pri starejših bolnikih odmerka ni treba prilagajati (glejte poglavje 5.2).
How to use Avamys 
Kako uporabljati zdravilo Avamys
Transient ocular changes (see Clinical experience), vision blurred (see also section 4.4) Respiratory, thoracic and mediastinal disorders Very common 
Očesne bolezni Ni znano prehodne očesne spremembe (glejte Klinične izkušnje), zamegljen vid (glejte tudi poglavje 4.4)
Data from large clinical trials were used to determine the frequency of adverse reactions. 
Pogostnost neželenih učinkov je bila določena na osnovi podatkov iz obsežnih kliničnih preskušanj.
Follow the guide carefully to get full benefit from using Avamys 
Natančno upoštevajte navodilo, da vam bo zdravilo Avamys koristilo v polni meri.
Based on these findings the average predicted exposure of 110 micrograms of intranasal fluticasone furoate in this patient population would not be expected to result in suppression of cortisol. 
Pri predvideni izpostavljenosti po nazalni uporabi flutikazonfuroata v odmerku 110 mikrogramov pri bolnikih z zmerno okvaro jeter supresije kortizola ne pričakujemo.
Nasal spray, suspension. 
pršilo za nos, suspenzija bela suspenzija
The recommended starting dose is two spray actuations (27.5 micrograms of fluticasone furoate per spray actuation) in each nostril once daily (total daily dose, 110 micrograms). 
Priporočeni začetni odmerek sta dva vpiha (27,5 mikrogramov flutikazonfuroata na vpih) v vsako nosnico enkrat na dan (skupni dnevni odmerek 110 mikrogramov).
Taking Avamys: 
Zdravilo Avamys:
How to use the nasal spray 
Kako uporabljati pršilo za nos
In addition, consideration should be given to referring the patient to a paediatric specialist (see section 
Presoditi je treba tudi o potrebnosti pregleda bolnika pri ustreznem specialistu (glejte poglavje 5.1).
 See Step-by-step guide to using the nasal spray, after Section 6. 
 Glejte podrobno Navodilo za uporabo pršila za nos na koncu poglavja 6.
2 Remove the cap by squeezing firmly on the sides of the cap with your thumb and forefinger- see picture e. 
Odstranite pokrovček tako, da ga s palcem in kazalcem trdno stisnete ob straneh - glejte sliko e.
Do not use Avamys if you are breast feeding unless your doctor or pharmacist tells you to. 
Če dojite, zdravila Avamys ne smete uporabljati, razen če vam tako svetuje zdravnik ali farmacevt.
Always keep the cap on. 
Pokrovček naj bo vedno nameščen.
Do not use Avamys if you are pregnant, or planning to become pregnant, unless your doctor or pharmacist tells you to. 
Če ste noseči ali nameravate zanositi, zdravila Avamys ne smete uporabljati, razen če vam tako svetuje zdravnik ali farmacevt.
The recommended starting dose is one spray actuation (27.5 micrograms of fluticasone furoate per spray actuation) in each nostril once daily (total daily dose, 55 micrograms). 
Priporočeni začetni odmerek je en vpih (27,5 mikrogramov flutikazonfuroata na vpih) v vsako nosnico enkrat na dan (skupni dnevni odmerek 55 mikrogramov).
14.2 ml Type I or Type III amber bottle (glass) fitted with a metering spray pump. 
14, 2-ml steklenička jantarne barve iz stekla tipa I ali III, opremljena z odmernim pršilnikom.
Contents of the pack and other information Step-by-step guide to using the nasal spray 
Shranjevanje zdravila Avamys Vsebina pakiranja in dodatne informacije Navodilo za uporabo pršila za nos
Elimination was primarily via the faecal route following oral and intravenous administration indicative of excretion of fluticasone furoate and its metabolites via the bile. 
Izločanje po peroralni ali intravenski uporabi poteka predvsem z blatom, kar kaže, da se flutikazonfuroat in njegovi presnovki izločajo z žolčem.
When to use Avamys 
Kdaj uporabljati zdravilo Avamys
Fluticasone furoate 110 micrograms once daily was not associated with hypothalamic-pituitary-adrenal (HPA) axis suppression in adult, adolescent or paediatric subjects. 
Uporaba flutikazonfuroata v odmerku 110 mikrogramov enkrat na dan pri odraslih, mladostnikih in otrocih ni bila povezana z zavoro osi hipotalamus-hipofiza-nadledvični žlezi.
As with all intranasal corticosteroids, the total systemic burden of corticosteroids should be considered whenever other forms of corticosteroid treatment are prescribed concurrently. 
Če se bolnik sočasno zdravi še s katerimkoli drugim kortikosteroidom, je, kot pri vseh nazalnih kortikosteroidih, treba upoštevati skupno sistemsko izpostavljenost kortikosteroidom.
Caution is recommended when co-administering fluticasone furoate with potent CYP3A inhibitors including cobicistat-containing products as an increase in the risk of systemic side effects is expected. 
Pri sočasni uporabi flutikazonfuroata in katerega od močnih zaviralcev CYP3A4, vključno z zdravili, ki vsebujejo kobicistat, priporočamo previdnost, saj je pričakovati večje tveganje sistemskih neželenih učinkov ne moremo izključiti.
Breast-feeding It is unknown whether nasal administered fluticasone furoate is excreted in human breast milk. 
Ni znano, če se flutikazonfuroat po nazalni uporabi izloča z materinim mlekom.
Fluticasone furoate nasal spray 110 micrograms once daily significantly improved ocular symptoms as well as improving patients' disease-related quality of life (RQLQ) compared to placebo in one study. 
V primerjavi s placebom je flutikazonfuroat v obliki pršila za nos v odmerku 110 mikrogramov enkrat na dan v eni študiji pomembno izboljšal tako očesne simptome kot tudi z boleznijo povezano kakovost življenja bolnika (RQLQ).
The device is primed by pressing the mist release button for at least six spray actuations (until a fine mist is seen), whilst holding the device upright. 
Pršilnik bolnik aktivira tako, da ga drži v pokončnem položaju in približno 6 krat pritisne na sprožilec (dokler se ne pojavi fina meglica).
At 110 micrograms, median concentrations in those subjects with quantifiable levels were 14.3 pg/ml and 14.4 pg/ml for 2-5 yrs and 6-11 yrs, respectively. 
Pri otrocih z merljivimi vrednostmi flutikazonfuroata po uporabi 110 mikrogramskega odmerka je bila pri otrocih, starih od 2 do 5 let, mediana vrednost koncentracij 14,3 pg/ml, pri otrocih, starih od 6 do 11 let, pa 14,4 pg/ml.
- Keep this leaflet. 
Odstranite pokrovček.
Mechanism of action: Pharmacotherapeutic group: Nasal preparations, corticosteroids. 
Farmakoterapevtska skupina: Zdravila za zdravljenje bolezni nosne sluznice, kortikosteroidi, oznaka ATC: R01AD12
• steroid tablets or injected steroids 
• kortikosteroide za injiciranje ali peroralno uporabo,
Median fluticasone furoate concentrations in those subjects with quantifiable levels at 55 micrograms were 18.4 pg/ml and 18.9 pg/ml for 2-5 yrs and 6-11 yrs, respectively. 
Pri otrocih z merljivimi vrednostmi flutikazonfuroata po uporabi 55 mikrogramskega odmerka je bila pri otrocih, starih od 2 do 5 let, mediana vrednost koncentracij 18,4 pg/ml, pri otrocih, starih od 6 do 11 let, pa 18,9 pg/ml.
Further, there were no treatment-related increases in the incidence of tumours in two year inhalation studies in rats and mice. 
Pri podganah in miših pri dveletnih študijah z uporabo zdravila v obliki inhalacij niso poročali o z zdravljenjem povezanem povečanju pojavnosti tumorjev.
Some people will not feel the full effects until several days after first using Avamys. 
Kdaj se pokažejo učinki zdravljenja z zdravilom Avamys Pri nekaterih bolnikih se popolni učinki zdravljenja pokažejo šele več dni po prvi uporabi zdravila Avamys, vendar zdravilo običajno začne učinkovati že v 8 do 24 urah po uporabi.
Hepatic Impairment No dose adjustment is required in patients with hepatic impairment (see section 5.2). 
Okvara jeter Pri bolnikih z okvaro jeter odmerka ni treba prilagajati (glejte poglavje 5.2).
Avamys nasal spray is used to treat symptoms of allergic rhinitis including stuffy, runny or itchy nose, sneezing and watery, itchy or red eyes, in adults and children aged 6 years and over. 
Avamys pršilo za nos uporabljamo pri odraslih in otrocih, starih 6 let in starejših, za zdravljenje simptomov alergijskega rinitisa, vključno z zamašenostjo nosu in izcedkom iz njega, srbenjem nosu, kihanjem, solzenjem in srbenjem ali pordelostjo oči.
Hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria. 
Bolezni imunskega sistema Redki preobčutljivostne reakcije, vključno z anafilaksijo, angioedemom, izpuščajem in urtikarijo
In vivo studies have revealed no evidence of cleavage of the furoate moiety to form fluticasone. 
S študijami in vivo cepitve furoata do flutikazona niso dokazali.
However, it may take several days of treatment to achieve maximum benefit, and the patient should be informed that their symptoms will improve with continuous regular use (see section 5.1). 
Bolniku je treba pojasniti, da se bodo simptomi izboljšali le pri neprekinjeni in redni uporabi (glejte poglavje 5.1).
Immune system disorders Rare 
Zelo redki perforacija nosnega pretina
Therefore, no clinical studies have been conducted to investigate interactions of fluticasone furoate on other drugs. 
Klinične študije, ki bi vrednotile interakcije med flutikazonfuroatom in drugimi zdravili, zato niso bile izvedene.
• Check the nasal spray for damage 
• Preverite pršilo za nos glede okvare.
Very rare 
Ni znano